



## Improving Pediatric Asthma Management by Utilizing a Scoring System and Care Pathway

Julie A. Brown and Kathleen Bryant, MD

### Disclosures

Julie Brown: Nothing to Disclose

Kathleen Bryant, MD: Nothing to Disclose





### Introduction

- Acute exacerbations of asthma are prevalent in pediatric population
- Differences in management exist among Emergency Department (ED) types and individual practitioners
- Pediatric Asthma Severity (PAS) scoring can guide therapeutic management and improve outcomes<sup>1</sup>

**AIM Statement**: Improve the efficiency of asthma exacerbation care in the Children's ED by decreasing the length of stay for patients presenting with acute asthma exacerbation by 10% in an initial 1-year period and 5% in subsequent years






### Methods

**Context**: Children's Emergency Department patients  $\geq 2$  years old with asthma exacerbation, October 2017-November 2020

 Gap analysis and fishbone diagram study were performed to identify and prioritize areas for improvement

#### PEDIATRIC ASTHMA SCORE (PAS)

	NORMAL	MILD		MODERATE	SEVERE
Scoring Factors	0	1		2	3
Respiratory Rate					
2-3 years	21-40	41-50		51-60	>61 or <20
4-5 years	19-34	35-44		45-54	>55 or <18
6-12 years	15-30	31-40		41-50	>51 or <14
> 12years	11-16	17-26		27-36	>37 or <10
Auscultation	Normal breath sounds with aeration throughout	End expira wheezes		Expiratory wheezing	Inspiratory and/or expiratory wheezing to diminished breath sounds
Retractions	None	Subcostal and/or substernal		Intercostal and/or supraclavicular	Suprasternal and/or sternal
Dyspnea	Speaks in complete sentences	Speaks in short sentences, coos and babbles		Speaks in partial sentences, short cry	Speaks in single words, short phrases or grunting
		4-6			
PAS	0-3	4-6		7-9	10 - 12
	0 - 3 ng alone suggests sever		y distress	Ne/Hilliam	
*Note: Head bobbi clinician	ng alone suggests sever		y distress	and mandates immed	iate evaluation by a
*Note: Head bobbi clinician	ng alone suggests sever			Exclusion Crit	iate evaluation by a
*Note: Head bobbi clinician Greater than or	ng alone suggests sever	e respirator	☐ Stride	Exclusion Crit	iate evaluation by a
*Note: Head bobbi clinician	ng alone suggests sever	e respirator	☐ Strido	Exclusion Critor  ry suggestive of foreignic lung disease: cystic	teria n body fibrosis, restrictive
*Note: Head bobbi clinician  Greater than on History of asth cough/wheeze	ng alone suggests sever	e respirator	Strido	Exclusion Crit or ry suggestive of foreig nic lung disease: cystic disease, bronchopulm	teria n body fibrosis, restrictive
*Note: Head bobbi clinician  Greater than or History of asthr cough/wheeze  *Must meet BOTH	ng alone suggests sever  nclusion Criteria  equal to 2 years old  na, albuterol use, or rec  inclusion criteria and Ni	e respirator current	☐ Strido ☐ Histor ☐ Chror	Exclusion Critorry suggestive of foreignic lung disease: cystic disease, bronchopulmental heart disease	n body fibrosis, restrictive onary disease
*Note: Head bobbi clinician  Greater than or History of asthr cough/wheeze  *Must meet BOTH	ng alone suggests sever nclusion Criteria equal to 2 years old na, albuterol use, or rec	e respirator current	☐ Stride ☐ Histor ☐ Chror lung c ☐ Conge	Exclusion Critor  ry suggestive of foreig ic lung disease: cystic disease, bronchopulm enital heart disease omical airway abnorm. ysis, tracheomalacia, t	teria  n body fibrosis, restrictive onary disease alities: vocal cord
*Note: Head bobbi clinician  Greater than or History of asthr cough/wheeze  *Must meet BOTH exclusion criteria to Care Pathway	ng alone suggests sever nclusion Criteria requal to 2 years old ma, albuterol use, or rec inclusion criteria and No o be eligible for the CED	e respirator current ONE of the Asthma	Stride Histor Chron lung c Conge	Exclusion Crit or ry suggestive of foreig icl ung disease: cystic isease, bronchopulmenital heart disease mical airway abnorm; ysis, tracheomalacia, t ident	ate evaluation by a  teria  n body fibrosis, restrictive ond visease alities: vocal cord racheostomy
*Note: Head bobbi clinician  Greater than or History of asthr cough/wheeze  *Must meet BOTH exclusion criteria to Care Pathway  *If the treating phy	ng alone suggests sever  nclusion Criteria  equal to 2 years old  na, albuterol use, or rec  inclusion criteria and Ni	current  ONE of the Asthma	Strido	Exclusion Critor  ry suggestive of foreig ic lung disease: cystic disease, bronchopulm enital heart disease omical airway abnorm. ysis, tracheomalacia, t	ate evaluation by a  teria  n body fibrosis, restrictive onary disease alities: vocal cord racheostomy inosuppression




#### **Primary Interventions/PDSA cycles:**

- 1. Implementation of **PAS scoring system**
- 2. Nursing staff and provider education on PAS risk stratification scoring system and Asthma Care Pathway (3 separate **education sessions**)
- 3. Implementation of **Asthma Care Pathway**
- Transformation of Asthma Care Pathway into EHR-compatible QuickTool





## Methods: Measuring Change



#### **Metrics and Measures:**

- Data Collection: chart audit in 2-month increments as four study periods:
  - October 2017 November 2017 (Pre-Intervention)
  - October 2018 November 2018
  - October 2019 November 2019
  - October 2020 November 2020
- Parameters evaluated:
  - Triage start time
  - Time to medication administration
  - Time to Discharge
  - Time to Admission
- Primary outcome measure: **Average ED Length of Stay (LOS)**






## Results

2020: OCTOBER -

NOVEMBER



2019: OCTOBER -

NOVEMBER

2018: OCTOBER -

NOVEMBER

0

2017: OCTOBER -

NOVEMBER

- Overall, average Length of Stay (LOS) was maintained for both discharged and admitted patients
- Year 1: LOS for <u>admitted</u> <u>patients</u> decreased by 8%
- Following incorporation of Asthma QuickTool, LOS decreased for all patients:
  - Admitted patients: 4.5%
  - Discharged patients: 4.9%





### Conclusion

 Use of an *integrated* asthma care pathway can decrease the length of stay for discharged patients and patients admitted to the hospital

**Future directions**: continue to trend data (seasonal variation), evaluate additional outcome/process measures, reincorporate education sessions